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Nitric oxide blunts myogenic autoregulation in rat renal
but not skeletal muscle circulation via tubuloglomerular
feedback
Armin Just and William J. Arendshorst
Department of Cell & Molecular Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7545, USA
This rat renal blood flow (RBF) study quantified the impact of nitric oxide synthase (NOS)
inhibition on the myogenic response and the balance of autoregulatory mechanisms in the
time domain following a 20 mmHg-step increase or decrease in renal arterial pressure (RAP).
When RAP was increased, the myogenic component of renal vascular resistance (RVR) rapidly
rose within the initial 7–10 s, exhibiting an ∼5 s time constant and providing ∼36% of perfect
autoregulation. A secondary rise between 10 and 40 s brought RVR to 95% total autoregulatory
efficiency, reflecting tubuloglomerular feedback (TGF) and possibly one or two additional
mechanisms. The kinetics were similar after the RAP decrease. Inhibition of NOS (by L-NAME)
increased RAP, enhanced the strength (79% autoregulation) and doubled the speed of the
myogenic response, and promoted the emergence of RVR oscillations (∼0.2 Hz); the strength
(52%) was lower at control RAP. An equi-pressor dose of angiotensin II had no effect on
myogenicortotalautoregulation. InhibitionofTGF(byfurosemide)abolishedthe L-NAMEeffect
on the myogenic response. RVR responses during furosemide treatment, assuming complete
inhibition of TGF, suggest a third mechanism that contributes 10–20% and is independent
of TGF, slower than the myogenic response, and abolished by NOS inhibition. The hindlimb
circulation displayed a solitary myogenic response similar to the kidney (35% autoregulation)
that was not enhanced by L-NAME. We conclude that NO normally restrains the strength and
speed of the myogenic response in RBF but not hindlimb autoregulation, an action dependent
on TGF, thereby allowing more and slow RAP fluctuations to reach glomerular capillaries.
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Autoregulation of blood flow is found in virtually
every tissue. The pressure-induced myogenic response
of vascular smooth muscle is an integral part of this
regulation (Johnson, 1986). The degree of autoregulation
varies between tissues and is particularly strong in the
kidney (Johnson, 1986). Autoregulation of renal blood
flow (RBF) is mediated by a tubuloglomerular feedback
(TGF) system in addition to the myogenic response (Navar
et al. 1996) and possibly a third regulatory component
(Just & Arendshorst, 2003). However, little is known
about the relative contribution of these mechanisms
to overall regulation and changes in their balance
in various situations. Micropuncture studies of single
nephron glomerular filtration rate (GFR) in the superficial
cortex have estimated that the myogenic response and
TGF contribute equally under basal conditions (Moore
et al. 1979). More recent transfer function analyses
of spontaneous fluctuations of RBF and renal arterial
pressure (RAP) indicate that both mechanisms are
active in vivo at the whole kidney level, albeit precise
quantification of the relative contributions is a limitation
of this technique (Ajikobi et al. 1996; Just et al. 1998). A
more reliable quantitative assessment is based on analysis
of transients of RBF to a rapid step change in RAP.
Such a dynamic analysis reveals approximately equal
participation of the myogenic response (55%) and TGF
(35–45%) in both dog and rat; a third system appears to
contribute about 10% during euvolaemia (Just et al. 2001;
Just & Arendshorst, 2003; Wronski et al. 2003).
Little is known about whether this balance between
the mechanisms is modulated, and, if so, what
the major modulating factors are. A shift in the
predominance of autoregulatory mechanisms is likely
to have important functional consequences because of
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their different response times. Whereas the myogenic
response to a step change in RAP is usually complete
within 10 s (Clausen et al. 1992; Young & Marsh, 1981),
TGF is much slower, with an initial delay of ∼10 s
and completion in 20–30 s (Daniels & Arendshorst,
1990). One or two additional regulatory components that
are of similar or even slower speed than TGF may also
be involved (Just & Arendshorst, 2003). Accordingly, a
more pronounced contribution of the fast myogenic
response would accelerate overall regulation and
prevent more and faster fluctuations of RAP from reaching
glomerular and peritubular capillaries. In this manner, the
myogenic response is poised to buffer changes in RAP on
glomerular filtration, pressure natriuresis, and glomerular
damage.
An attractive paracrine candidate for such a modulating
role is nitric oxide (NO). NO exerts a strong tonic dilator
effect that is more pronounced in the kidney than in other
vascular beds (Sonntag et al. 1992; Sigmon et al. 1993).
On the other hand, acute inhibition of NO production
has little, if any, effect on steady-state RBF autoregulation
(Beierwaltes et al. 1992; Majid & Navar, 1992; Baumann
et al. 1992). Nevertheless, subtle NO-dependent effects
are evident as a reduction in the lower pressure limit of
autoregulation during NOS-inhibition (Turkstra et al.
2000; Kramp et al. 2001). Isolated renal vessel studies using
blood-free perfusates indicate that NO can attenuate the
myogenic response (Imig et al. 1993; Bouriquet & Casellas,
1995; Juncos et al. 1995), although others have failed to
detect such an effect of NO. The NO effects, however, seem
to be limited to certain vascular segments (Imig & Roman,
1992; Hoffend et al. 1993) and others have not detected
a modulatory effect of NO (Hayashi et al. 1995; Yip &
Marsh, 1996). Perfusion with haemoglobin-containing
solutions usually attenuates the impact of NO in isolated
preparations. At the whole kidney level in vivo, transfer
function analyses of regulatory mechanisms suggest a more
active myogenic response in the absence of NO (Wang et al.
1999; Wang & Cupples, 2001), although such assessments
are not well suited to reliably estimate the overall
autoregulatory efficiency and the contributions of
individual mechanisms (Bidani et al. 2003). Mathematical
modelling of the dynamics of RBF responses to a step
increase in RAP after complete ischaemia also suggests NO
counteracts myogenic contrictor responsiveness (Wronski
et al. 2003).
Although an attenuating effect of NO on the myogenic
response is reported for several extrarenal vessels including
skin (Griffith & Edwards, 1990), myocardium (Rubanyi
et al. 1986; Ueeda et al. 1992; Pohl et al. 1994), mesentery
(Pohl et al. 1991), spleen (Brookes & Kaufman, 2003) and
skeletal muscle (Johnsson et al. 1991; de Wit et al. 1998;
Nurkiewicz & Boegehold, 1999) other studies failed to
confirm this particularly in the skeletal muscle circulation
(Falcone et al. 1991; Ekelund et al. 1992; Sun et al. 1994).
An aim of the present in vivo study was to quantify the
impact of NOS inhibition on the relative contributions
of myogenic response and TGF to RBF autoregulation
in the time domain. To this end, we employed small
changes in RAP within the autoregulatory range and our
data analyses were independent of modelling assumptions.
Another goal was to determine whether the modulatory
influence of NO on the myogenic response was dependent
on TGF activity. A third objective was to test whether
NO inhibition enhanced the myogenic response in the
hindlimb circulation as it did in the kidney.
Methods
Experiments were conducted on 23 male Sprague-Dawley
rats (age 9–15 weeks, body weight 320–470 g, left kidney
weight 1.6–2.4 g) from our local breeding colony (18
rats) or purchased from Charles River Laboratories Inc.
(Raleigh, NC, USA; 5 rats) and were approved by the
Institutional Animal Care and Use Committee of the
University of North Carolina. The animals were fed a
standard lab chow with free access to tap water, and
were kept on a 12 h : 12 h light–dark cycle. Surgery and
experimental procedures were similar to those reported
earlier (Just & Arendshorst, 2003).
Surgical procedures
After induction of anaesthesia by pentobarbital
(50–60 mg (kg body wt)−1 i.p., Nembutal, Abbott,
Chicago, IL, USA), a rat was placed on a temperature-
controlled table kept at 37

C. The depth of anaesthesia
was monitored by the response to ear and toe pinching.
Additional doses of pentobarbital (3–8 mg kg−1 i.v.) were
given as needed (∼every 30–60 min). The left femoral
artery was catheterized (PE-50) to measure arterial
pressure, and three catheters (PE-10) were placed into
the left femoral vein for infusion of volume replacement
and injections of pentobarbital, and drugs. An isoncotic
bovine serum albumin solution (4.75 g dl−1) was infused
initially at 100 µl min−1 to replace surgical losses (1.25 ml
(100 g body wt)−1), followed by a maintenance rate of
5 µl min−1 (100 g body wt)−1. The trachea was cannulated
(PE-240) to facilitate respiration. Via a midline abdominal
incision, the abdominal aorta, left renal artery, and origins
of right renal and superior mesenteric artery were
exposed. An inflatable vascular occluder (1.5 mm; IVM,
Healdsburg, CA, USA) was implanted around the aorta
above the left renal artery. In six rats an additional
occluder was implanted above the coeliac artery. A
non-cannulating flowprobe (1 RB; Transonic, Ithaca,
NY, USA) was placed around the left renal artery and
filled with ultrasonic coupling gel (HR Lubricating Jelly;
Carter-Wallace, New York, NY, USA). In five animals, an
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additional flowprobe of the same type was placed on the
left iliac artery. A 23-gauge needle with a catheter (PE-50)
allowed bladder urine to drain by gravity. Sixty minutes
were allowed for stabilization after surgery.
Pressure in the left renal artery (RAP) was measured
via the femoral artery catheter and a pressure transducer
(Statham P23B). Renal blood flow (RBF) and blood flow
in the iliac artery (IBF) were measured with flowprobes
connected to ultrasound transit-time flowmeters (TS-420
for RBF, T-206 for IBF; Transonic, low-pass filter set
to 30–40 Hz). Zero offset was determined at the end of
each experiment after cardiac arrest. The pressure in the
vascular occluder was monitored by a transducer (MSP
3101P2-ND; Measurement Specialties Inc., Fairfield, NJ,
USA) to allow for automatic detection of the time points
of increase or decrease in RAP. All data were recorded on
a computer (Pentium III, DataTranslation A/D converter,
Labtech Notebook-Pro) at 100 Hz (RAP and RBF) or 10 Hz
(occluder pressure). Urinary flow was measured using a
graduated cylinder.
The autoregulatory response of RBF to a rapid change
of RAP within the autoregulatory pressure range was
measured after RAP was reduced by 20 mmHg with
controlled inflation of the aortic occluder for a period of
60 s. A 20 mmHg step increase in RAP then was produced
by rapid deflation of the occluder. RAP reductions were
repeated every 5 min, thus allowing 4 min for recovery. At
least three RAP steps were made in each period. At the
conclusion of the experiments the animals were killed by
an overdose of pentobarbital (> 150 mg kg−1 i.v.).
Experimental protocols
Group A. NOS-inhibition (n = 8). To investigate the effect
of NO on the myogenic response and the dynamics of RBF
autoregulation, the NOS inhibitor Nω-nitro-l-arginine
methyl ester (l-NAME) was injected (25 mg kg−1 in
1 ml kg−1 saline i.v.) after a control period. After
l-NAME, there was a 15 min equilibration period. Since
NOS-inhibition elevates baseline RAP, we wanted to
separate direct effects of l-NAME from those of elevated
RAP and to test for pressure dependency of NO inhibitory
effects. Thus, baseline RAP was reduced in a third
experimental period to match the control level before
addition of l-NAME by either inflating an additional
proximal occluder (4 rats) or by partially pre-inflating a
single occluder (4 rats). After an equilibration period of
5–10 min, 20 mmHg RAP steps were superimposed on the
restored level of RAP.
Group B. Angiotensin II (n = 6). Since NOS inhibition
produces vasoconstriction, similar experiments were
conducted in which similar degrees of hypertension and
renal vasoconstriction were induced by i.v. infusion of
Ang II (100 ± 24 ng kg−1min−1). Previous studies indicate
that a pressor dose of Ang II has only minor effects on
the dynamics of RBF autoregulation (Just et al. 2002). A
period of 15 min was allowed for equilibration after final
dose adjustment. Subsequently, the baseline level of RAP
was reduced to match the control level before addition of
Ang II by inflation of an aortic occluder. After the target
RAP was reached, 5–10 min were allowed for stabilization.
Group C. NOS inhibition during TGF inhibition (n = 4).
To test whether the effects of NOS inhibition on RBF
autoregulatory dynamics are intrinsic to the myogenic
response or depend on an intact TGF, l-NAME was
given during inhibition of TGF by furosemide. After a
control period, the albumin solution was diluted 1 : 10 with
isotonic saline for volume replacement, the infusion rate
was increased to 50 µl−1 kg−1 min−1 and furosemide was
injected (10 mg kg−1 in 1 ml kg−1 saline i.v.; American
Regent Laboratory Inc., Shirley, NY, USA). Urine output
was measured every 5 min and the infusion rate was
adjusted to match urine flow. To avoid augmentation
of TGF by volume contraction (Schnermann & Briggs,
1990), the cumulative infused volume was intentionally
kept 1–2 ml above that of the excreted urine. After
a 15 min equilibration period, at least three step
responses were recorded. Subsequently, l-NAME was
injected (25 mg kg−1 i.v.) and, after 15 min equilibration,
additional step responses were recorded.
Group D. Effect of NOS inhibition in the hindlimb
circulation and TGF inhibition during NOS inhibition
(n = 5). To determine whether the observed effects of
NOS inhibition are a generalized phenomenon or unique
to the kidney, l-NAME (25 mg kg−1 i.v.) was given to a
group of rats in which IBF was measured simultaneously
with RBF. After the control and l-NAME periods,
furosemide was injected (10 mg kg−1 i.v.) in a third
period, the infusion rate adjusted as described above, and
step responses recorded after an equilibration period of
15 min.
Data analysis
Data analyses were done off-line by dedicated computer
programs. The 100 Hz data of RAP and RBF were
smoothed by a sliding average over 100 values each.
Zero-offsets of RBF and IBF were subtracted from
the recorded values. RVR was calculated as RPP/RBF,
where renal perfusion pressure (RPP) = RAP − 4 mmHg;
4 mmHg was assumed as renal venous pressure. These
data sets of RAP, RBF and RVR were then resampled to a
sampling rate of 10 Hz. Short segments were then extracted
into single files for each RAP reduction containing the
last 10 s before RAP reduction, followed by the segment
between the last 10 s before release through 120 s after
release. For analysis of the responses to a RAP decrease,
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Table 1. Baseline values of haemodynamic parameters and urine excretion during the experimental periods
Experimental period n MAP RBF HR UV
(mmHg) (ml min−1 gKW−1) (beats min−1) (µl min−1)
Control 8 108 ± 2 6.4 ± 0.3 391 ± 7 18 ± 3
L-NAME 8 136 ± 4∗ 2.8 ± 0.3∗∗∗ 382 ± 11 19 ± 3
L-NAME + RAP-servo 8 111 ± 2# 2.8 ± 0.3∗∗∗ 383 ± 16 17 ± 6
Control 6 109 ± 4 6.1 ± 0.6 362 ± 19 29 ± 7
Ang II 6 133 ± 3∗∗∗ 3.5 ± 0.4∗∗∗ 352 ± 24 41 ± 15
Ang II + RAP-servo 6 112 ± 3### 3.1 ± 0.3∗∗∗ 355 ± 33 34 ± 6
Control 4 123 ± 4 6.3 ± 0.5 313 ± 15 24 ± 4
Furosemide 4 122 ± 4 6.2 ± 0.3 304 ± 12 344 ± 16∗∗∗
Furosemide + L-NAME 4 139 ± 4∗∗, ## 4.4 ± 0.4∗∗∗, ### 312 ± 42 523 ± 47∗∗∗, ##
Control 5 118 ± 3 5.1 ± 0.4 317 ± 18 12 ± 2
L-NAME 5 147 ± 8∗∗ 2.3 ± 0.3∗∗∗ 264 ± 16∗∗ 15 ± 6
L-NAME + Furosemide 5 131 ± 6 3.7 ± 0.6∗∗, ## 275 ± 20∗∗ 471 ± 87∗∗∗, ###
∗,∗∗,∗∗∗: P < 0.05, P < 0.01, P < 0.001 versus respective control;#, ##, ###: P < 0.05, P < 0.01, P < 0.001 versus
preceding group. gKW−1, per gram kidney weight.
segments were extracted containing the data from 10 s
before RAP reduction until the time of RAP release. The
exact time points for reduction and release of RAP were
derived from changes in the occluder pressure, i.e. at an
accuracy of ±10 ms. Baseline values given in Table 1 are the
mean values during the last 10 s before each RAP reduction
of a particular experimental period, except for urine flow
rates, which are averaged over an observation period.
The first and second derivatives of RVR were calculated
by the Savitzky-Golay algorithm (Savitzky & Golay, 1964)
with a window size of 11 points and coefficients for 3rd
order fitting. The speed of the myogenic response was
derived from the average 1st derivative between 2 and 3 s
after the RAP step. To account for changes in baseline RVR
as well as differences from resistance of IBF (IVR), changes
in RVR and IVR in ((mmHg (ml min−1)−1) s−1) were
normalized by dividing through the respective baseline
resistance in (mmHg (ml min−1)−1); accordingly, results
are expressed as fractional resistance change in normalized
units per second (U s−1).
The contribution of the myogenic response was
estimated from the RVR change reached within 7–10 s after
the RAP reduction and 7–9 s after RAP release. These time
windows were chosen based on previous results (Just &
Arendshorst, 2003) as well as on the present data, in which
the transition between the initial (myogenic response) and
the secondary (TGF) and possible other autoregulatory
mechanisms was determined from the time of lowest speed
of RVR adaptation between 3 and 10 s after the RAP step,
as derived from the zero-crossing of the 2nd derivative of
RVR. The exact time of zero-crossing was determined from
the individual time course of the 2nd derivative of RVR
during control conditions of each animal by calculating a
linear regression over the values between 3 and 10 s and
subsequent arithmetic determination of the zero-crossing
of the regression line.
Autoregulatory efficiency was expressed as a percentage
of perfect autoregulation, with 100% denoting a RVR
adjustment matched to keep RBF exactly constant
in the face of a change in RAP; 0% indicates
unchanged RVR and the absence of autoregulation.
The efficiency of total RBF autoregulation was calculated
as (RVRend − RVRpre)/[(RPPend/RBFpre) – RVRpre] × 100,
where RPPpre, RBFpre and RVRpre are averages for the last
10 s before release of the aortic occluder, and RVRend and
RPPend are the average values during 90–120 s after the
step increase in RAP. As a measure of the autoregulation
provided by the myogenic response, the same formula was
applied but instead of RVRend, the RVR averaged at 7–10 s
was used. Autoregulatory efficiency for the response to
decreased RAP was calculated by taking for RPPpre, RBFpre
and RVRpre the averages for the last 10 s before RAP
reduction, and for RVRend and RPPend the average values
during 50–60 s after RAP reduction.
Within the initial 1 s after the increase or decrease in
RAP, RVR transiently changed in opposite direction to
the following autoregulatory response, which most likely
reflects passive distention or collapse of the resistance
vessels. To determine the time point of maximum or
minimum RVR during this period as a measure of the
delay time of the active response, the first derivative was
calculated from the time course of changes in RVR. A linear
regression was then calculated over all derivative values
versus time between t = 0.2 s and t = 0.8 s. Zero-crossing
of this regression line indicated the time of maximum or
minimum RVR.
Statistical analysis
The effects of experimental interventions were determined
by comparison of the results from the respective
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experimental periods within the same animal. Statistical
significance was tested by ANOVA for repeated measures
in conjunction with the Holm-Sidak test (SigmaStat 3.10,
SPSS Inc., Chicago, IL, USA). In the case of non-normal
distribution, data were log-transformed before testing. If
the speed of the myogenic response was not normally
distributed by log-transformation (‘l-NAME’ and ‘All
l-NAME’ groups), the Tukey test for multiple comparisons
was used as a post hoc test. A P value < 0.05 was
considered statistically significant. Data are represented
as mean ± s.e.m.
Results
We characterized the myogenic response and the efficiency
of blood flow autoregulation in the renal and hindlimb
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Figure 1. Step responses of renal blood flow autoregulation. Influence of NO and angiotensin II
Time course of renal artery pressure (RAP) and of the autoregulatory response of renal vascular resistance during
a step increase (A, C and E) and a step decrease (B, D and F) of RAP by 20 mmHg. A and B, time course of RAP
during control ( ), during NOS inhibition by L-NAME (•), and during L-NAME with mechanical restoration of RAP
to the control level (line without circles), n = 8. C and D, responses of vascular resistance to the pressure steps
shown in A and B during control ( ), L-NAME (•), and L-NAME with restoration of RAP (line without circles), n = 8.
E and F, responses during control ( ), during infusion of Ang II to match the pressor and renal vasoconstrictor
effects of L-NAME (•), and during Ang II with restoration of RAP (line without circles), n = 6. Mean (continuous
lines) ± S.E.M. (dashed lines).
vasculature based on the dynamics of the time-dependent
changes in vascular resistance after a rapid 20 mmHg
step change of RAP. Absolute values of MAP, RBF, heart
rate (HR) and urine flow for the individual groups
are summarized in Table 1. The normal autoregulatory
response pattern of RVR as a function of time is shown in
the control curves of Figs 1–3. When RAP was increased,
RVR transiently fell, and then rapidly rose within the
first 7–10 s to provide 32–41% of perfect autoregulation
(Figs 1A and C, 2A, 3C and 4; Table 2). After a short
delay, a secondary rise brought RVR to the final level
of actual autoregulatory strength of 95% for all control
animals (n = 23) (Table 2). As we have noted earlier (Just
& Arendshorst, 2003), these temporal characteristics are
consistent with the notion that the myogenic response
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Figure 2. Step responses of renal blood flow autoregulation. Influence of NO in the absence of TGF
Time course of the autoregulatory response of renal vascular resistance to a step increase (A) and a step decrease
(B) of renal artery pressure (RAP) during control (line without circles), during TGF inhibition by furosemide ( ), and
during furosemide combined with NOS inhibition by L-NAME (•). Mean (continuous lines) ± S.E.M. (dashed lines),
n = 4.
mediates the initial rise in RVR, with slower responses due
to TGF and possibly a third mechanism. The transition
between the initial and secondary responses, determined
from the turning point of RVR changes, was at 8.6 ± 0.4 s.
Further analysis of these data indicates that the maximum





















































































Figure 3. Step responses of hindlimb and renal blood flow autoregulation. Influence of NO and TGF
Time course of the autoregulatory response of vascular resistance in response to a step increase (A and C) and
a step decrease (B and D) of arterial pressure in the hindlimb (A and B) and in the kidney (C and D). Responses
during control ( ), during NOS inhibition by L-NAME (•) and during additional TGF inhibition by furosemide (lines
without circles). Mean (continuous lines) ± S.E.M. (dashed lines), n = 5.
speed of the myogenic response was 2.8 U s−1 (Table 2).
In response to step reduction of RAP, RVR fell in a
quantitatively similar fashion, except that the myogenic
response provided an autoregulatory efficiency of 62%
(P < 0.001 versus RAP increase) (Figs 1B and D, 2B, and
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3D; Table 3). The turning point between the myogenic
response and TGF was 9.6 ± 1.1 s. A more detailed
comparison between the dynamics of the responses to
increase and decrease of RAP is given in Fig. 5, showing
the time course of the initial 10 s from the control
periods for all 23 rats. The maximum or minimum RVR
during the initial transient change of RVR indicating the
delay time before beginning of the active vasoconstriction
or –dilation, occurred slightly earlier in response to the
increase (∼0.4 s) than to the decrease in RAP (∼0.6 s,
Fig. 5). Determination of the maximum/minimum RVR
from the first derivative for each animal revealed that
the delay times were statistically different (0.39 ± 0.01
versus 0.53 ± 0.05 s, P < 0.001). Choosing different time
windows between 0 and 1.1 s for the regression analysis of
the time point (see Methods) gave similar results. The time
course of the subsequent active responses was slightly faster
for the dilator response to an decrease of RAP than for the
constriction to an increase of RAP; bi-exponential fitting of
the averaged time courses detected only mono-exponential
dynamics with shorter time constants for the dilator (2.6 s)
than the constrictor response (5.1 s).
l-NAME inhibition of NOS produced vasoconstriction,
reducing RBF by 50% and increasing RAP by 25%
(Table 1). A major finding was that the renal myogenic
response was enhanced to provide an autoregulatory
efficiency of 79% (Figs 1A and 4, Table 2). In addition,
the myogenic response was accelerated; the slope of the
initial RVR change was enhanced 2- to 3-fold (Fig. 1A,
Table 2). Thus, removing the attenuating effects of NO
affected both the speed and the strength of the myogenic
response. Accordingly, the myogenic response accounted
for a larger fraction of autoregulation in a shorter period
of time: 79% was achieved within 4 s (Fig. 1A, Table 2).
Total autoregulatory efficiency increased slightly. It is
noteworthy that NOS inhibition led to the emergence
of oscillations of RVR with a cycle length of 4–5 s,
i.e. 0.20–0.25 Hz, an observation compatible with reduced
restraint of a well-damped second-order control system
or transition from a first- to a second-order system. The
consistency of such oscillations averaged for eight animals
is remarkable, indicating that they are highly synchronized
and reproducible.
Normalizing the elevated RAP during NOS inhibition
to the control level of 102 mmHg attenuated the enhanced
myogenic response (52 versus 79%, P < 0.05, Figs 1A
and 4, Table 2). Complete restoration was seen in
some of the animals. In contrast, acceleration of the
myogenic adaptation was not affected by the RAP
reduction, remaining 2- to 3-fold greater than control
(Table 2).
The effects of NOS inhibition on the RVR responses
to a step decrease of RAP were similar in general to
values recorded when RAP was increased. The strength of
the myogenic response was enhanced by NOS inhibition
(84 versus 59%, P < 0.05, Figs 1B and 4, Table 3).
Enhancement of the speed, which doubled numerically
(Table 3), is apparent in the time course (Fig. 1B).
Since NOS inhibition exerted potent systemic and renal
vascular effects, control experiments were conducted in
which similar amounts of renal vasoconstriction and
hypertension were produced by Ang II. The responses
are shown in Fig. 1C, and numerical means are given
in Table 2 and Fig. 4. Ang II affected neither the strength
nor the speed of the myogenic response (32%, 2.8 U s−1,
respectively). Subsequent RAP reduction to the basal level
had no influence on the myogenic response, as was the
case for total autoregulatory efficiency. Likewise, Ang II
had no effect on RVR responses to the RAP step reduction
(Fig. 1D, Table 3).
To test whether the effects of NO are intrinsic to the
renal myogenic response or depend on TGF, l-NAME
was given after inhibition of TGF by furosemide. As is
shown in Fig. 2A and summarized in Table 2, furosemide
alone reduced overall autoregulation by 43% and tended
to augment the myogenic response, indicating effective
inhibition of TGF and its contribution to RBF auto-
regulation. An important observation was that l-NAME
failed to augment the renal myogenic response when TGF
was inhibited. The strength of the myogenic response
remained constant (44 versus 45%, Figs 2A and 4,
Table 2) while NO inhibition produced the same systemic
pressor effect as noted earlier in Group A (+25 versus
+26%, Table 1). Likewise, NOS inhibition failed to








































































































Figure 4. Autoregulatory strength of the myogenic response in
renal and hindlimb blood flow
Strength of the myogenic response as derived from the autoregulatory
efficiency reached at 7–10 s following a step increase of renal artery
pressure (RAP). Open bars denote results in control conditions for each
experimental group. Other bars show data during NOS inhibition by
L-NAME (filled bar, L-NAME) alone and with mechanical normalization
of RAP (striped bar, + RAP-servo), during infusion of Ang II alone (filled
bar, Ang II) and with normalization of RAP (striped bar, + RAP-servo),
during TGF inhibition by furosemide alone (hatched bar, Furosemide)
and with L-NAME (filled bar, L-NAME), during L-NAME alone (filled bar,
L-NAME) and with furosemide (cross-hatched bar, + Furosemide) in
the kidney, and the latter also in the hindlimb. Mean ± S.E.M.
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Table 2. Characteristics of renal and hindlimb blood flow autoregulation in response to a step increase of
RAP
Total Myogenic response Myogenic response
Step increase n autoregulation autoregulation Maximum speed
Experimental period (% of perfect AR) (% of perfect AR) (units s−1)
Control 8 93 ± 6 37 ± 6 2.5 ± 0.4
L-NAME 8 110 ± 10 79 ± 13∗∗ 5.4 ± 0.6∗
L-NAME + RAP-servo 8 102 ± 6 52 ± 11# 7.5 ± 2.5∗
Control 6 92 ± 6 32 ± 6 2.8 ± 0.4
Ang II 6 87 ± 8 39 ± 6 2.8 ± 0.4
Ang II + RAP-servo 6 95 ± 6 40 ± 9 3.7 ± 0.8
Control 4 106 ± 12 41 ± 5 2.6 ± 0.6
Furosemide 4 63 ± 6∗∗ 45 ± 4 2.9 ± 0.6
Furosemide + LNAME 4 51 ± 15∗∗∗ 44 ± 12 3.8 ± 0.7∗
Control 5 95 ± 2 41 ± 9 3.6 ± 0.3
L-NAME 5 112 ± 5 93 ± 10∗∗ 16.5 ± 7.0∗
L-NAME + Furosemide 5 40 ± 13∗∗∗, ### 47 ± 12### 9.1 ± 3.6
Hindlimb − Control 5 35 ± 5[ 30 ± 5 4.9 ± 0.1
Hindlimb − L-NAME 5 37 ± 7[ 26 ± 4[ 3.3 ± 0.3
Hindlimb - 5 55 ± 7∗, # 50 ± 14 4.1 ± 0.8
L-NAME + Furosemide
All controls 23 95 ± 4 37 ± 3††† 2.8 ± 0.2
Control 13 94 ± 4 38 ± 5 2.9 ± 0.3
All L-NAME 13 111 ± 6∗∗∗ 85 ± 9∗∗∗ 9.7 ± 3.0∗
Control 9 100 ± 6 41 ± 5 3.1 ± 0.3
All L-NAME + Furosemide 9 45 ± 8∗∗∗,2++ 46 ± 82+ 6.7 ± 2.1∗
∗,∗∗,∗∗∗: P < 0.05, P < 0.01, P < 0.001 versus respective control;#, ##, ###: P < 0.05, P < 0.01, P < 0.001 versus
preceding group; [P < 0.01 hindlimb versus kidney; †††P < 0.001 versus step decrease of RAP (Table 4);
2+,2++: P < 0.01, P < 0.001 ‘All L-NAME’ versus ‘All L-NAME + Furosemide’; ‘units s−1’ = RVR/baseline
RVR/time = (mmHg (ml min−1)−1) (mmHg (ml min−1)−1)−1 s−1.
during furosemide administration in the response to step
reduction of RAP (Fig. 2B, Table 3).
A potentially important result is that a slow component
of RVR adaptation persisted, participating in the
secondary rise of RVR after 10 s and accounting for
15–20% of total autoregulation during furosemide
inhibition of TGF (Table 2). These findings provide
evidence for a contribution of a third mechanism, a
system that is independent of TGF and slower than
the myogenic response. Interestingly, NOS inhibition
eliminated this third component of RVR adaptation,
reducing its participation from 21 to 8% of total auto-
regulation (P < 0.05, Fig. 2A), indicating that this sluggish
mechanism is mediated by or dependent on NO. A
similar trend was seen after a step reduction of RAP
(Table 3).
In other animals we tested whether inhibition of TGF
would reverse the augmenting effect of NOS inhibition on
the myogenic response. Figures 3C and 4 show that NOS
inhibition by l-NAME reproduced the results seen earlier
(Figs 1A and 4) as the myogenic response was markedly
enhanced (93 versus 41%, Table 2), accelerated 4-fold,
and oscillations were unmasked. The same tendencies
were seen following a step reduction of RAP (Fig. 3D) as
l-NAME impacted on the myogenic response in terms
of oscillations (Fig. 3D), strength (81 versus 62%) and
acceleration (6.8 versus 3.3 U s−1) (Table 3).
In this same group we also tested the effects of NOS
inhibition on myogenic autoregulation in the hindlimb
vascular bed. Iliac blood flow (IBF) displayed auto-
regulatory responses to a 20 mmHg step increase in AP
that was weaker than for the renal circulation (35 versus
95%, P < 0.01, Figs 3A and 4, Table 2). Over the initial 10 s,
IBF autoregulation was similar to that of the kidney, except
for a more pronounced overshoot in IBF. Importantly,
there was no secondary rise of hindlimb resistance, and
the final level of IBF autoregulation (35%) was similar
to the myogenic response of the hindlimb and the kidney
(30 and 41%, respectively, Fig. 4, Table 2). Collectively, our
results suggest that small, brief step changes of perfusion
pressure elicit autoregulation in the hindlimb that is due
predominately, if not entirely, to the myogenic response.
Moreover, the myogenic response in the hindlimb has
the same strength and speed as in the renal circulation.
In contrast, the myogenic mechanism in the kidney is
supported by TGF and probably a third regulator. Another
difference between vascular beds is the impact of NOS
inhibition on the myogenic responses.
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Table 3. Characteristics of renal and hindlimb blood flow autoregulation in response to a step reduction of RAP
Total Autoregulation by the Myogenic response
Step decrease n autoregulation myogenic response Maximum speed
Experimental period (% of perfect AR) (% of perfect AR) (units s−1)
Control 8 86 ± 6 59 ± 5 −3.6 ± 0.5
L-NAME 8 99 ± 8 84 ± 7∗ −6.9 ± 2.5
L-NAME + RAP-servo 8 99 ± 6 66 ± 9 −5.2 ± 1.5
Control 6 87 ± 8 63 ± 6 −3.4 ± 0.5
Ang II 6 87 ± 7 53 ± 3 −4.0 ± 1.2
Ang II + RAP-servo 6 90 ± 7 62 ± 11 −3.7 ± 1.6
Control 4 108 ± 9 65 ± 1 −2.8 ± 0.2
Furosemide 4 62 ± 3∗∗∗ 55 ± 5 −2.1 ± 0.5
Furosemide + LNAME 4 55 ± 7∗∗∗ 52 ± 14 −3.5 ± 1.9
Control 5 95 ± 8 62 ± 10 −3.3 ± 0.7
L-NAME 5 100 ± 6 81 ± 9 −6.8 ± 1.3
L-NAME + Furosemide 5 43 ± 14∗∗, ## 37 ± 13# −2.6 ± 0.4#
Hindlimb – Control 5 39 ± 3[$ 66 ± 12 −2.5 ± 1.8
Hindlimb – L-NAME 5 36 ± 7[ 45 ± 11[ −3.4 ± 1.4
Hindlimb - 5 72 ± 12∗, # 54 ± 11 −2.7 ± 1.8
L-NAME + Furosemide
All controls 23 92 ± 4 62 ± 3††† −3.3 ± 0.3
Control 13 89 ± 5 60 ± 5 −3.5 ± 0.4
All L-NAME 13 99 ± 5∗ 83 ± 6∗∗∗ −6.9 ± 1.5
Control 9 101 ± 6 63 ± 5 −3.1 ± 0.4
All L-NAME + Furosemide 9 48 ± 8∗∗∗,2++ 44 ± 9∗,2+ −3.0 ± 0.8+
∗,∗∗,∗∗∗: P < 0.05, P < 0.01, P < 0.001 versus respective control;#, ##, ###: P < 0.05, P < 0.01, P < 0.001 versus
preceding group; [,[$: P < 0.01, P < 0.001 hindlimb versus kidney; †††P < 0.001 versus step-increase of RAP (Table 3);
+,2+,2++: P < 0.05, P < 0.01, P < 0.001 ‘All L-NAME’ versus ‘All L-NAME + Furosemide’; ‘units s−1’ = RVR/baseline
RVR/time = (mmHg (ml min−1)−1) (mmHg (ml min−1)−1)−1 s−1.
As noted earlier in Group A, inhibition of NOS
augmented and accelerated renal autoregulation. IBF
autoregulation, however, was not affected by l-NAME,
even though absolute IBF was reduced (Figs 3A and
4, Table 4). The speed of the adaptation was also not
altered (Table 2). Similar IBF results were obtained when
perfusion pressure was reduced (Fig. 3B, Table 3). For
unknown reasons, the myogenic response and total auto-
regulation in the hindlimb tended to increase during
furosemide administration (Figs 3B and 4, Table 2).
Discussion
The present study provides new information that the
balance between the regulating mechanisms of RBF
autoregulation is dynamic not static and that NO is an
important modulating factor capable of changing the
balance in a healthy kidney. NO markedly attenuates the
strength, speed and oscillations of the myogenic response
to changes in renal perfusion pressure in the kidney.
NO normally restrains the contribution of the myogenic
response to overall autoregulation of RBF, thereby slowing
the speed of adaptive changes in preglomerular vascular
resistance and allowing more and slower fluctuations of
RAP to reach glomerular and postglomerular capillaries.
The responses to 20 mmHg increases and decreases in RAP,
which were intentionally kept within the autoregulatory
range, are symmetrical, indicating that RBF autoregulation
is designed to buffer changes in mean RAP and respond
similarly to systolic and diastolic RAP. Further insight
into this interaction derives from a dependency of NO
dampening on the level of RAP and a functional TGF. In
contrast, the hindlimb circulation devoid of TGF has a
myogenic response that is similar in strength and speed as
that in the kidney and is unaffected by the absence of NO.
The characteristics of the myogenic response are derived
from the autoregulatory adaptation of RVR occurring
within the initial 7–10 s after a rapid step change of RAP
as previously employed (Just & Arendshorst, 2003). This
analysis is based on the known response time of the renal
myogenic response (Young & Marsh, 1981; Clausen et al.
1992) and initial 10 s delay of TGF (Daniels & Arendshorst,
1990). Such a time lag between mechanisms is evident
in the transition between the two distinct phases of RVR
between 7 and 10 s in the control curves. This conclusion
is reinforced by the finding that the secondary rise of RVR
is almost abolished by inhibition of TGF with furosemide
(Just et al. 2001; Just & Arendshorst, 2003; Wronski et al.
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2003), whereas the rapid myogenic response is enhanced,
not reduced (Just & Arendshorst, 2003; Wronski et al.
2003). Collectively, these points support the view that the
rise of RVR within the first 7–10 s reflects the myogenic
response without an obvious contribution from TGF.
The step changes in RAP were intentionally kept small
(20 mmHg) to assure testing within the autoregulatory
pressure range. Our results for control conditions confirm
our previous observations during euvolaemia that the
myogenic response provides an efficiency of 30–40% of
perfect autoregulation, corresponding to ∼50% of the
observed autoregulatory strength of the kidney (Just &
Arendshorst, 2003).
The major new finding is that NOS inhibition
markedly augments and accelerates the contribution of the
myogenic response to overall blood flow autoregulation in
the kidney, while causing minor to no improvements in
total autoregulatory efficiency. That the improved auto-
regulation within the first 7–10 s was due to an acceleration
of TGF rather than an augmentation of the myogenic
response seems unlikely, because there are no indications
that the dynamics of TGF change during NOS inhibition;
TGF-associated oscillations in the transfer function remain
clearly visible around 0.03 Hz at the same centre frequency
as during control conditions. Furthermore, the effects
of NOS inhibition on the myogenic response cannot be
ascribed to the vasoconstrictor effects of l-NAME because
no such modulation was observed during infusion of
Ang II that produced identical effects on baseline RAP and
RBF, in agreement with a previous report (Just et al. 2002).
Our quantitative studies extend earlier reports of NOS
inhibition augmenting the strength of the myogenic





















































Figure 5. Comparison of the dynamics of the myogenic
response to a step increase and step decrease of renal artery
pressure (RAP)
Time course of RAP (A) and of the autoregulatory response of renal
vascular resistance (B) during the initial 10 s after step increase (•) and
step decrease ( ) of RAP, averaged from the control periods of all rats.
Mean ± S.E.M., n = 23.
Table 4. Absolute values of baseline blood flow in the left renal
(RBF) and iliac artery (IBF) in protocol D
Experimental period n RBF IBF
(ml min−1) (ml min−1)
Control 5 8.9 ± 0.8 2.9 ± 0.2
L-NAME 5 3.9 ± 0.6∗∗∗ 1.8 ± 0.1∗∗∗
L-NAME + Furosemide 5 6.4 ± 1.0∗∗, ## 1.6 ± 0.1∗∗∗
∗∗,∗∗∗: P < 0.01, P < 0.001 versus respective control;## P < 0.01
versus preceding group.
et al. 1999; Wang & Cupples, 2001). The improved
autoregulatory efficiency of the myogenic response in
our RAP step responses corresponds well with the
fractional compensation calculated from transfer gain at
0.06–1.0 Hz. However, a major change in transfer gain
during NOS inhibition was not found in dogs (Just et al.
1999). The reasons for the variable results are not clear
but may derive from species differences, from imposed
forced (Wang et al. 1999; Wang & Cupples, 2001) versus
spontaneous fluctuations of RAP (Just et al. 1999), or
from using shorter (Wang et al. 1999; Wang & Cupples,
2001) or longer (Just et al. 1999) time segments for
spectral calculations. Another possibility is a masking of
improved myogenic autoregulation by superimposition
of feedback oscillations of TGF, which seem to be more
prominent in dogs (Just et al. 1998, 1999) than in rats
(Wang et al. 1999; Wang & Cupples, 2001). Moreover, it
should be appreciated that there are concerns about the
reliability of the absolute level of the transfer gain in the low
frequency range as an accurate measure of autoregulatory
efficiency (Bidani et al. 2003). These reservations highlight
the importance of using more quantitative, direct methods
such as that used in the present study.
Our data clearly show that NOS inhibition increased
the speed of the myogenic response and also led to strong
and reproducible and highly synchronized oscillations of
RVR. The accelerated myogenic response agrees with a
slight shift of the corner frequency associated with the
myogenic response in the transfer function (Just et al.
1999; Wang & Cupples, 2001). Transfer function analysis
also shows an elevated transfer gain at the same frequency
in the absence of NO, consistent with enhanced feedback
oscillations (Just et al. 1999; Wang et al. 1999; Wang &
Cupples, 2001). However, from transfer functions alone,
it cannot be decided whether the elevated gain might also
be caused by enhanced vascular compliance. In this regard,
the present results in the time domain clearly demonstrate
the emergence of strong and synchronized oscillations in
the absence of NO.
The negligible effect of NOS inhibition on total
autoregulatory efficiency fits nicely with classical RBF
studies reporting unaltered steady-state autoregulatory
efficiency in the absence of NO (Majid & Navar, 1992;
Beierwaltes et al. 1992; Baumann et al. 1992).
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The absence of direct modulation of the myogenic
response by NO in the absence of TGF activity is congruent
with studies on isolated afferent arterioles (Yip & Marsh,
1996) or the hydronephrotic kidney (Hayashi et al. 1995).
At variance, however, are other studies on isolated vessels
(Juncos et al. 1995), the hydronephrotic kidney (Hoffend
et al. 1993) or interlobular arteries in the juxtamedullary
nephron preparation (Imig et al. 1993; Bouriquet &
Casellas, 1995). Although the reasons for the discordant
results are not clear, it should be appreciated that when
an effect of NO was detected, NO levels were either
raised experimentally (Bouriquet & Casellas, 1995) or
may have been artificially elevated due to the use of
erythrocyte-free perfusates that lack the NO scavenging
effect of haemoglobin (Imig et al. 1993; Juncos et al. 1995).
In fact, the effect of NOS inhibition could be mimicked by
adding erythrocytes to the perfusate in one study (Imig
et al. 1993). A mitigating effect of NO when elevated but
not when reduced is consistent with the observation that
steady-state RBF autoregulation of the intact kidney is
impaired by infusion of acetylcholine (Baer et al. 1970), but
well maintained during NOS inhibition (Majid & Navar,
1992; Beierwaltes et al. 1992; Baumann et al. 1992).
Furthermore, we investigated the influence of the
ambient RAP level on NO effects and found that
mechanical restoration of RAP to normotensive levels
during NOS inhibition attenuated the increase in the
strength of the myogenic response. The reason for this
pressure dependency of NO effects is not clear, but may be
secondary to reduced TGF activity at the reduced RAP.
TGF is known to be stronger at higher levels of RAP
(Schnermann & Briggs, 1989). Even though the myogenic
response was numerically larger during NOS inhibition
with servo-controlled RAP than during control conditions,
it did not reach statistical significance. However, transfer
function studies reported a significant enhancement of the
myogenic response in the absence of NO even when the
concomitant hypertension was prevented by servo-control
of RAP (Wang & Cupples, 2001). Pressure dependency
was not addressed in that study as observations were
not made at elevated RAP. In contrast to our finding
that the myogenic strength is pressure dependent, the
enhancement of the speed of the myogenic response during
NOS inhibition was not affected by restoration of the RAP.
This is in line with findings of transfer function analysis
of an augmented slope of gain reduction between 0.2 and
0.06 Hz during NOS inhibition with servo-controlled RAP
(Wang & Cupples, 2001).
A surprising finding was that NOS inhibition abolished
the slow adaptation of RVR occurring after 10 s during
furosemide application. The fact that this slow adaptation
was present after the myogenic response was complete and
during furosemide inhibition of TGF confirms previous
findings suggesting participation of a third mechanism to
RBF autoregulation (Just et al. 2001; Just & Arendshorst,
2003). The elimination of this response by NOS inhibition
indicates mediation by NO. This is particularly intriguing
with regard to previous observations in dogs indicating
a regulatory function of NO in a frequency range lower
than TGF (Just et al. 1999). Future studies are necessary to
further characterize this regulatory component.
Although we cannot exclude that the slow component
of autoregulation observed during furosemide treatment
between 10 and 30 s reflects remnant TGF function due to
incomplete blockade of TGF, this seems unlikely for two
reasons. First, doubling the dose of 10 mg kg−1 furosemide
did not induce additional effects in a previous study
(Just & Arendshorst, 2003). Second, given the well-known
attenuating effect of NO on TGF (Wilcox et al. 1992;
Thorup et al. 1993), it is difficult to understand why NOS
inhibition would eliminate rather than enhance a remnant
activity of TGF.
It should be noted that there is another, even
slower, component of autoregulation seen during control,
l-NAME, and Ang II, reflected by the rise of RVR between
40 and 120 s. This putative fourth component is clearly
TGF dependent, since it is abolished by furosemide (Fig. 2;
Just & Arendshorst, 2003). A possible explanation is a
progressive reduction of proximal tubular reabsorption
occurring with a rise of RAP (Walstead & Yip, 2004).
This might lead to a slowly increasing tubular load
and macula densa signal, thus inducing a progressive
secondary TGF-mediated vasoconstriction. However, it
seems unlikely that this slow rise of RVR from ∼80–95%
of perfect autoregulation between 40 and 120 s can explain
the increase in RVR between 10 and 30 s in the absence of
TGF.
Another important observation concerns our analysis
of the dynamics of the myogenic response of RBF in the
whole kidney in vivo (Fig. 5) as compared with those
reported for changes in afferent arteriolar diameter in
the saline-perfused chronically hydronephrotic kidney
(Loutzenhiser et al. 2002). Loutzenhiser et al. found a
more rapid myogenic response to an 80 mmHg increase
in RAP than an 80 mmHg decrease due to a shorter delay
in diameter change (0.3 versus 1 s) and differing time
constants: mono-exponential (4 s) for constriction and
bi-exponential (1 s and 14 s) for dilatation. As a result,
they concluded that afferent arteriolar autoregulation
is more responsive to systolic than to mean RAP. In
contrast, our data show that the dilator response was
stronger overall with a shorter time constant (2.6 s) than
the constrictor response (5.1 s). If these dynamics are
the only determinants for the responsiveness to systolic
versus mean pressure, then our results would speak against
a preferential response to systolic pressure, congruent
with earlier studies that did not detect an influence of
pulse pressure on RBF autoregulation (Selkurt, 1951;
Ritter, 1952). However, the initial delay time was slightly
longer for the dilator versus the constrictor response (0.53
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versus 0.39 s), a difference considerably smaller than that
reported for the hydronephrotic kidney (1.0 versus 0.3 s)
(Loutzenhiser et al. 2002). Loutzenhiser et al. believe the
difference in delay time is the major determinant for
the preferential response to systolic pressure, although
it was not tested whether their model retains the same
characteristics when only different delay times are included
and time constants are set equal. Taken together, our
data confirm a longer delay time for the dilator than for
the constrictor action of the myogenic response in the
renal vasculature for integrated RBF in the intact kidney.
However, the difference in delay times is rather small
and further investigation is required to determine if it is
responsible for any preferential response to systolic versus
mean pressure.
With regard to the conclusion that the NO action on
the myogenic response is entirely dependent on an active
TGF, one would expect that the myogenic response in
an extrarenal vascular bed devoid of TGF would not
be affected by NOS inhibition. Previous studies of the
hindlimb circulation found no enhancement of myogenic
responsiveness during NOS inhibition in a blood-perfused
preparation (Ekelund et al. 1992). This is also the case
for isolated skeletal muscle arterioles after removal of the
endothelium (Falcone et al. 1991; Sun et al. 1994). On the
other hand, many studies have reported attenuating effects
of NO on myogenic responsiveness and autoregulation in
vascular beds of skin (Griffith & Edwards, 1990), coronary
(Rubanyi et al. 1986; Ueeda et al. 1992; Pohl et al. 1994),
mesenteric (Pohl et al. 1991; Brookes & Kaufman, 2003),
and skeletal muscle (Rubanyi et al. 1986; Johnsson et al.
1991; de Wit et al. 1998; Nurkiewicz & Boegehold, 1999).
It is of interest that NOS inhibition enhanced myogenic
responsiveness of large-diameter arteries in the cremaster
circulation, whereas myogenic tone of small arterioles
was unaffected (de Wit et al. 1998). In view of the
conflicting results for the skeletal muscle circulation, we
investigated the autoregulatory responses in the hindlimb
simultaneously with those in the kidney.
Our results demonstrate that autoregulation of the
hindlimb circulation displays a similar response time and
strength to the myogenic response in the kidney. It seems
very likely therefore that the responses in this non-renal
vascular bed to small, brief RAP changes reflect mainly, if
not exclusively, the myogenic response. Importantly, these
regulatory responses were not affected by NOS inhibition,
in marked contrast to the enhancement of the renal
myogenic response in the same animals. This occurred
while both IBF and RBF were reduced by NO inhibition.
Accordingly, we conclude that NO, presumably endothelial
in origin, does not affect the myogenic response in the
hindlimb circulation. Our results are consistent with the
lack of effect of NOS inhibition on the myogenic response
in blood-perfused skeletal muscle preparation (Ekelund
et al. 1992), in contrast to an effect reported for a cell-
free perfusate (Johnsson et al. 1991). The finding that
the reduction of baseline flow was less pronounced in
the hindlimb than in the kidney agrees with the literature
(Sonntag et al. 1992; Sigmon et al. 1993).
Collectively, our results indicate that NO attenuates
the myogenic response in renal autoregulation but not
in skeletal muscle. This effect is largely dependent on
TGF and is more prominent at higher levels of RAP.
Signalling pathways of this effect of NO may be the
same as those known to mediate the general vasodilator
effects of NO, i.e. activation of soluble guanlylate cyclase,
cGMP and cGMP-dependent kinase (Carvajal et al. 2000;
Schlossmann et al. 2003), which have been shown to affect
Ca2+-entry, -release and -sensitivity, as well as modulating
factors of smooth muscle contraction such as cAMP,
phospholipase C, protein kinase C and large conductance
K+ (BK) channels (Carvajal et al. 2000; Schlossmann
et al. 2003). In addition, cGMP-independent, direct
inhibition of cytochrome P450-induced production of
20-hydroxyeicosatrienoic acid (20-HETE) and subsequent
reduced inhibition of BK channels (Zou et al. 1996) or
reduced activation of rho kinase (Randriamboavonjy et al.
2003) could also play a role. However, studies in the
hydronephrotic kidney suggest that cGMP-independent
pathways may be of minor importance for the effects of
endothelial-derived NO in the afferent arteriole (Trottier
et al. 1998).
What is not clear is how NO affects myogenic
responsiveness in conjunction with TGF. One intriguing
hypothesis is that NO derived from macula densa
cells rather than endothelial cells is responsible for the
effects of NO. The reason why macula densa-derived
NO might have more impact than endothelial-derived
NO might involve the microenvironment of the juxta-
glomerular apparatus and more ready accessibility from
basolateral versus luminal aspects of the afferent arteriole.
Another possibility that might contribute to the putative
preferential influence of NO from the macula densa is that
NO may not affect the myogenic response directly but
rather may act on a target that is more easily accessible by
NO from the macula densa than from the endothelium.
Such a target, e.g. macula densa cells themselves (Ren
et al. 2000) or mesangial cells, may then release a non-NO
mediator. Future studies are required to test the relative
potency of NO derived from neuronal NOS in macula
densa cells on the renal myogenic response as compared
with endothelial NOS. Another explanation for the TGF
dependency of the NO effect might be that TGF signals
during resting or elevated tubular NaCl concentrations
condition the myogenic response to be more susceptible
to the effects of NO, irrespective of NO origin.
In view of the ability of NO to attenuate TGF, at least at
high tubular flow rates (Wilcox et al. 1992; Thorup et al.
1993), it may seem surprising that the balance between
the autoregulating mechanisms is shifted towards
C© 2005 The Authors. Journal compilation C© 2005 The Physiological Society
J Physiol 569.3 NO blunts renal myogenic autoregulation via TGF 971
the myogenic response rather than TGF during NOS
inhibition. A possible explanation is that the myogenic
response is faster and upstream of TGF, so it effectively
buffers a pressure perturbation and thus minimizes an
error signal reaching TGF. Accordingly, the myogenic
response would dominate autoregulation, unless it is
restrained by processes such as interactions with TGF
(Schnermann & Briggs, 1989; Kallskog & Marsh, 1990;
Just & Arendshorst, 2003). NO might act to increase the
strength of these interactions and thereby attenuate the
dominance of the myogenic response. One possibility
of such NO-modulated coupling is by gap junctions.
However, NO appears to suppress rather than enhance
gap junction communication (Bolanos & Medina, 1996;
Kameritsch et al. 2005). It should also be kept in mind
that enhanced TGF tone does not necessarily imply large
autoregulatory efficiency of TGF, if the operating point
is at one of the saturation ends of TGF (Thomson et al.
2004). Another possible explanation that could contribute
to our results is interaction between TGF-mediated
vasoconstriction of the terminal afferent arteriole and
myogenic responses at more upstream sites as proposed in
the concept of ascending myogenic response (Moore et al.
1994). According to this view, a localized vasoconstriction
not only reduces intraluminal pressure distal from that
site but also flattens the profile of intravascular pressure
upstream. Thus, any change in RAP would cause a
larger initial change in intraluminal pressure in the
proximal vascular segments and subsequently elicit an
enhanced myogenic response. If NOS inhibition were to
induce localized vasoconstriction of the terminal afferent
arteriole, the ascending myogenic response could explain
or contribute to the enhanced myogenic autoregulation
during NOS inhibition in our results. Although there
is little information on the distribution of the effects of
NOS inhibition along the renal vascular tree, available in
vitro data are compatible with localized constriction at
the end of the afferent arteriole (Imig & Roman, 1992).
Interestingly, the constrictor effects of NOS inhibition
are more uniform along the preglomerular vasculature in
preparations devoid of TGF (Hoffend et al. 1993).
Although we have no measure of TGF tone in our in vivo
setting, the finding of a vasodilator response to TGF
inhibition during l-NAME addition as compared with
the lack of such effect in the normal animal suggests
enhanced TGF tone in the absence of NO. Since the effect
of TGF is confined to the most distal part of the afferent
arteriole (Casellas & Moore, 1990), and NO is known to
attenuate TGF (Wilcox et al. 1992; Thorup et al. 1993),
NOS inhibition via activation of TGF may cause localized
vasoconstriction and thereby enhanced myogenic
autoregulation via the ascending myogenic response.
However, our observation that infusion of Ang II failed to
affect myogenic autoregulation despite an identical degree
of overall renal vasoconstriction as l-NAME, speaks
against this hypothesis, unless it is postulated that Ang II
causes more uniform vasoconstriction along the vascular
tree, even though it is also known to enhance TGF (Huang
& Navar, 1988). To date, reports on the effects of Ang II are
variable, favouring either homogenous distribution along
the preglomerular vasculature (Carmines et al. 1986) or a
preferential action on the distal afferent arteriole (Casellas
et al. 1985). Clearly, more work needs to be done to more
completely understand the intriguing effects of NO on
RBF autoregulation in the whole kidney described in the
present study.
Perspectives
As a whole, our data provide new information about
NO attenuating the myogenic response in the normal
kidney with an intact TGF and possibly mediating a third
mechanism distinct from myogenic and TGF. The ability
of NO to dampen myogenic tone is dependent on an active
TGF. By restraining the myogenic response to changes
in RAP, TGF and the third mechanism assume larger
roles at the expense of decelerating overall autoregulation.
The slower autoregulation allows a greater amount and a
slower type of RAP fluctuations to reach glomerular and
postglomerular capillaries. The ability of NO to attenuate
the strength and the speed of the myogenic response
impacts on glomerular filtration, pressure natriuresis and
hypertensive renal damage.
It is worth noting that a role of NO in pressure natriuresis
is well established (Evans et al. 2005) and the modulation
of the balance between autoregulating mechanisms
might be a contributing mechanism. Furthermore, RBF
autoregulation in Brown-Norway rats, a rat strain highly
susceptible to hypertensive renal damage (Churchill et al.
1997), has a weak, attenuated myogenic response, a defect
that can be corrected by NOS inhibition (Wang & Cupples,
2001). Similar effects could play a role in Fawn-hooded
rats, that are genetically predisposed to glomerulosclerosis
and show a weak myogenic response and slow
autoregulation (van Dokkum et al. 1999), or early in
diabetes mellitus, which is accompanied by an increased
risk for glomerulosclerosis and evidence for elevated renal
levels of NO (Komers & Anderson, 2003).
Our hindlimb data clearly show the absence of any
modulating influence of physiological levels of NO on
myogenic autoregulation in the skeletal muscle circulation.
This agrees with the only other in vivo study investigating
the effect of NO on myogenic responsiveness on total
organ blood flow (Ekelund et al. 1992). On the contrary,
many studies detecting an enhancement of myogenic
responsiveness during NOS inhibition were performed
in vitro using cell-free perfusion media, which may have
caused supranormal levels of NO both in skeletal muscle
(Johnsson et al. 1991) and in other organs (Griffith &
Edwards, 1990; Ueeda et al. 1992; Pohl et al. 1994; Imig
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et al. 1993). It appears that an augmentation of myogenic
responsiveness in response to NOS inhibition particularly
occurs in those tissues and vessel segments in which
myogenic responses are weak or absent normally (Griffith
& Edwards, 1990; de Wit et al. 1998; Brookes & Kaufman,
2003). This emphasizes the importance of validating in
vitro findings of single vessels by in vivo blood flow
studies.
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